TOP Web Exclusives

In April 2017, midostaurin (Rydapt) was approved for the treatment of adults with newly diagnosed FLT3-positive AML in combination with standard intensive induction consolidation chemotherapy.

“Mogamulizumab demonstrated convincing clinical activity, not just in skin but also in clearing malignant T-cells in the blood and lymph nodes. PFS and overall global response outcomes are clearly superior,” said Dr Kim.

Although this response rate is “substantial,” said Dr Przepiorka, the investigators wanted to know whether this drug could be added to the standard-of-care chemotherapy regimen known as ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), or should it replace bleomycin in this regimen.

Acalabrutinib received FDA approval on October 31, 2017, for patients with mantle-cell lymphoma but not for patients with CLL. It is only the second BTK inhibitor to receive approval by the FDA.

A total of 389 patients were randomized to oral venetoclax 400 mg once daily, given until disease progression or unacceptable toxicity, for a maximum of 2 years, plus rituximab for 6 cycles versus 6 cycles of bendamustine plus rituximab. In the venetoclax arm, the dose was gradually increased to 400 mg daily over 4 to 5 weeks to reduce the likelihood of tumor lysis syndrome.

Lead investigator Joseph M. Connors, MD, FRCPC, Clinical Director, Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, Canada, reported the results of the phase 3 ECHELON-1 clinical trial, which were also published online (Connors JM, et al. N Engl J Med. 2018;378:331-344) to coincide with the ASH meeting.

Among patients with untreated follicular lymphoma, 75% achieved complete responses with the 3-drug combination of atezolizumab (Tecentriq), obinutuzumab (Gazyva), and bendamustine (Treanda), results of a small, preliminary clinical trial reported at ASH 2017 showed.

Of the 24 patients receiving sotatercept monotherapy, 20 had primary myelofibrosis. Their median baseline hemoglobin level was 7.5 g/dL.

This week Sellas Life Sciences Group announced data from a study of NeuVax (nelipepimut-S) in combination with Herceptin (trastuzumab) in patients with HER2 1+/2+ breast cancer.
There were a number of areas where we asked the forecast panelists questions specifically regarding oncology, and how the changing environment might relate to oncology pharmacists.
Page 1 of 2
Results 1 - 10 of 13